Capillary whole blood measurement of islet autoantibodies

被引:26
作者
Bazzigaluppi, E
Bonfanti, R
Bingley, PJ
Bosi, E
Bonifacio, E
机构
[1] Ist Sci San Raffaele, Dept Med 1, I-20123 Milan, Italy
[2] Ist Sci San Raffaele, Dept Paediat, I-20123 Milan, Italy
[3] Univ Bristol, Dept Med, Bristol, Avon, England
关键词
D O I
10.2337/diacare.22.2.275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Islet cell antibody (ICA) measurements in serum are used for large-scale screening to identify subjects who are at high risk of developing type 1 diabetes. The aim of this study was to adapt measurements to capillary whole blood samples to facilitate and reduce screening costs. RESEARCH DESIGN IND METHODS - GAD65, IA-2, and combined GAD65/IA-2 antibody tests were performed on patients with type 1 diabetes, first-degree relatives of patients, and control subjects, and results from serum, plasma, whole venous blood, and capillary whole blood lysates were compared. Measurements obtained in serum and eluates from dried capillary blood spots from 36 ICA(+) first-degree relatives were also compared. RESULTS - GAD65, IA-2, and combined GAD65/IA-2 antibody levels were completely concordant with measurements obtained from serum, plasma, whole venous blood, and capillary whole blood lysates. Antibody levels obtained in eluates from dried capillary blood spots were lower than corresponding serum samples, and weak antibodies were not detected. CONCLUSIONS - Initial screening for diabetes risk can be performed using one drop of capillary whole blood without further processing to separate serum. This method should be considered as a way to simplify and reduce costs of screening programs.
引用
收藏
页码:275 / 279
页数:5
相关论文
共 19 条
[1]  
BLAND M, 1995, INTRO MED STAT, P269
[2]   ISLET AUTOANTIBODY MARKERS IN IDDM - RISK ASSESSMENT STRATEGIES YIELDING HIGH-SENSITIVITY [J].
BONIFACIO, E ;
GENOVESE, S ;
BRAGHI, S ;
BAZZIGALUPPI, E ;
LAMPASONA, V ;
BINGLEY, PJ ;
ROGGE, L ;
PASTORE, MR ;
BOGNETTI, E ;
BOTTAZZO, GF ;
GALE, EAM ;
BOSI, E .
DIABETOLOGIA, 1995, 38 (07) :816-822
[3]  
BONIFACIO E, 1995, J IMMUNOL, V155, P5419
[4]   ISLET-CELL ANTIBODIES IN DIABETES-MELLITUS WITH AUTOIMMUNE POLY-ENDOCRINE DEFICIENCIES [J].
BOTTAZZO, GF ;
FLORINCH.A ;
DONIACH, D .
LANCET, 1974, 2 (7892) :1279-1283
[5]   Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins [J].
Christie, MR ;
Roll, U ;
Payton, MA ;
Hatfield, ECI ;
Ziegler, AG .
DIABETES CARE, 1997, 20 (06) :965-970
[6]   GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives [J].
Dittler, J ;
Seidel, D ;
Schenker, M ;
Ziegler, AG .
DIABETES, 1998, 47 (04) :592-597
[7]   ICA512 AUTOANTIBODY RADIOASSAY [J].
GIANANI, R ;
RABIN, DU ;
VERGE, CF ;
YU, LP ;
BABU, SR ;
PIETROPAOLO, M ;
EISENBARTH, GS .
DIABETES, 1995, 44 (11) :1340-1344
[8]  
GORSUCH AN, 1981, LANCET, V2, P1363
[9]  
GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469
[10]   Evaluation of islet cell antigen (ICA) 512/IA-2 autoantibody radioassays using overlapping ICA512/IA-2 constructs [J].
Kawasaki, E ;
Yu, LP ;
Gianani, R ;
Verge, CF ;
Babu, S ;
Bonifacio, E ;
Eisenbarth, GS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :375-380